- Kimberly-Clark’s Q4 adjusted earnings per share (EPS) were $1.50, slightly missing the $1.52 estimate.
- Net sales for Q4 came in at $4.93 billion, beating the estimate of $4.85 billion.
- Net sales in North America were reported at $2.72 billion.
- International Personal Care net sales reached $1.38 billion.
- International Family Care and Professional net sales totaled $831 million.
- The company expects its fiscal year (FY) 2025 EPS to grow at a mid-to-high single digit rate.
- FY 2025 EPS forecasts account for a negative impact of 320 basis points due to the divestiture of PPE and exit from the US private label diaper businesses.
- There is an additional negative impact projected at 100 basis points from below operating profit factors like higher net interest expenses, a higher effective adjusted tax rate, and fewer shares outstanding.
- Kimberly-Clark anticipates FY 2025 organic sales growth to exceed the roughly 2% growth in its competitive categories and countries.
- FY 2025 reported net sales are expected to be negatively impacted by approximately 300 basis points due to currency translation.
- The exit from PPE and private label diaper businesses is projected to negatively impact reported net sales by 240 basis points.
- Analyst recommendations on Kimberly-Clark stock include 6 buys, 13 holds, and 2 sells.
“`
Kimberly Clark on Smartkarma
Analysts on Smartkarma, like Baptista Research, are providing insightful coverage of Kimberly-Clark Corporation. In a recent report titled “Kimberly-Clark Corporation: Strategic Growth Plan Leveraging Major Brands & New Market Initiatives! – Major Drivers,” Baptista Research highlighted the mixed performance of Kimberly-Clark in the third quarter of 2024. The report emphasized the strategic progress made by the company amidst notable challenges.
CEO Mike Hsu’s discussion on earnings showcased successful advances in Kimberly-Clark’s Powering Care strategy. This strategy focuses on positioning the company as a global leader in its categories through innovation, productivity optimization for growth initiatives, and organizational restructuring for enhanced efficiency and competitiveness. The analysis offers valuable insights for investors looking to understand Kimberly-Clark’s strategic direction and performance in the market.
A look at Kimberly Clark Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Kimberly Clark, a global health and hygiene company known for its wide range of consumer products, has received varying Smart Scores across different factors. With a strong emphasis on dividends and growth potential, the company has secured a solid score in these areas. Investors looking for stable returns and potential growth opportunities may find Kimberly Clark appealing based on these scores. However, factors such as value and resilience have received lower scores, indicating areas that may require further attention or analysis to ensure a well-rounded investment strategy.
Kimberly-Clark Corporation, a leading manufacturer of consumer products including diapers, tissues, and surgical gowns, operates in numerous countries worldwide. The company’s Smart Scores reflect a positive outlook on aspects related to dividends and growth, highlighting its potential for delivering returns and expanding its market presence. Despite facing challenges in terms of value and resilience, Kimberly Clark‘s diverse product portfolio and global reach position it as a prominent player in the health and hygiene industry, offering investors opportunities to capitalize on its strengths and navigate potential risks.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
